CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for HeXun Biosciences Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

HeXun Biosciences Co Ltd
6F
No.1490, Chunri Road, Taoyuan District
Phone: +886 33175088p:+886 33175088 TAOYUAN, 330  Taiwan Ticker: 69866986
Business Summary
HeXun Biosciences Co Ltd is a Taiwan-based company primarily engaged in the drug development business. The Company's products and services are mainly new drug development and sales, contract development and manufacturing services, testing services and other services. The Company's cellular products are categorized into allogeneic mesenchymal stem cell drugs and autologous cell medical technology development cellular products. The Company is also engaged in the provision of aseptic filling services, Good Tissue Practice (GTP) laboratory setup and quality documentation counseling services, and laboratory information management systems. The Company sells its products and services primarily domestically.
(Source: N-30D)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202312/31/2022-----

Industries
SIC Code Description
2834 Pharmaceutical preparations
2836 Biological products, except diagnostic substances
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board ZhenghaWen 3/22/2024
General Manager Chi-HungHuang 3/22/2024
Deputy General Manager WanxinChen 4/26/2024 4/26/2024
3 additional Officers and Directors records available in full report.

General Information
Outstanding Shares: 46,000,000 (As of 9/7/2023)
Stock Exchange: TPO
Fax Number: +886 33175089


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, April 27, 2024